Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashwin N Ananthakrishnan

Showing results (71-80 of 418) with videos related to

Pageof 42
Sort By:
Digestive Diseases and Sciences|June 12, 2021
High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel DiseasesAlexa N Sasson, Ashwin N Ananthakrishnan
The American Journal of Gastroenterology|November 15, 2017
"Weekend Effect" in Patients With Upper Gastrointestinal Hemorrhage: A Systematic Review and Meta-analysisAshutosh Gupta, Rajender Agarwal, Ashwin N Ananthakrishnan
Biometrics|May 16, 2020
Robust and efficient semi-supervised estimation of average treatment effects with application to electronic health records dataDavid Cheng, Ashwin N Ananthakrishnan, Tianxi Cai
Journal of Crohn'S & Colitis|January 18, 2025
Assessment and reporting of extraintestinal manifestations and fatigue in phase 3 inflammatory bowel disease clinical trialsTarun Chhibba, Karan Sachdeva, Ashwin N Ananthakrishnan
Inflammatory Bowel Diseases|January 3, 2020
Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel DiseaseAmy Yu, Sonia Friedman, Ashwin N Ananthakrishnan
Inflammatory Bowel Diseases|May 20, 2020
Characteristics and Long-Term Outcomes of Pregnancy-Onset Inflammatory Bowel Disease: A Case-Control StudyAmy Yu, Sonia Friedman, Ashwin N Ananthakrishnan
Digestive Diseases and Sciences|July 30, 2024
Risk Factors for the Development of and Outcomes After Diagnosis of Autoimmune Alopecia Areata in Patients with Inflammatory Bowel DiseasesYushan Pan, Evelyn Lilly, Ashwin N Ananthakrishnan
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2020
Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort StudyAmar Vedamurthy, Nikitha Gangasani, Ashwin N Ananthakrishnan
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 25, 2024
Outcomes of Long-term Tumor Necrosis Factor Alpha Inhibitor Therapy Beyond 10 Years in Inflammatory Bowel DiseaseQuinten Dicken, Mmeyeneabasi Omede, Ashwin N Ananthakrishnan
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 13, 2025
A Comprehensive Review of Geriatric Syndromes and Assessment in Older Adults With Inflammatory Bowel DiseasesMargalida Calafat, Bharati Kochar, Ashwin N Ananthakrishnan
Pageof 42

Showing results (71-80 of 418) with videos related to

Sort By:
Pageof 42
Digestive Diseases and Sciences|June 12, 2021
High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel DiseasesAlexa N Sasson, Ashwin N Ananthakrishnan
The American Journal of Gastroenterology|November 15, 2017
"Weekend Effect" in Patients With Upper Gastrointestinal Hemorrhage: A Systematic Review and Meta-analysisAshutosh Gupta, Rajender Agarwal, Ashwin N Ananthakrishnan
Biometrics|May 16, 2020
Robust and efficient semi-supervised estimation of average treatment effects with application to electronic health records dataDavid Cheng, Ashwin N Ananthakrishnan, Tianxi Cai
Journal of Crohn'S & Colitis|January 18, 2025
Assessment and reporting of extraintestinal manifestations and fatigue in phase 3 inflammatory bowel disease clinical trialsTarun Chhibba, Karan Sachdeva, Ashwin N Ananthakrishnan
Inflammatory Bowel Diseases|January 3, 2020
Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel DiseaseAmy Yu, Sonia Friedman, Ashwin N Ananthakrishnan
Inflammatory Bowel Diseases|May 20, 2020
Characteristics and Long-Term Outcomes of Pregnancy-Onset Inflammatory Bowel Disease: A Case-Control StudyAmy Yu, Sonia Friedman, Ashwin N Ananthakrishnan
Digestive Diseases and Sciences|July 30, 2024
Risk Factors for the Development of and Outcomes After Diagnosis of Autoimmune Alopecia Areata in Patients with Inflammatory Bowel DiseasesYushan Pan, Evelyn Lilly, Ashwin N Ananthakrishnan
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2020
Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort StudyAmar Vedamurthy, Nikitha Gangasani, Ashwin N Ananthakrishnan
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 25, 2024
Outcomes of Long-term Tumor Necrosis Factor Alpha Inhibitor Therapy Beyond 10 Years in Inflammatory Bowel DiseaseQuinten Dicken, Mmeyeneabasi Omede, Ashwin N Ananthakrishnan
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 13, 2025
A Comprehensive Review of Geriatric Syndromes and Assessment in Older Adults With Inflammatory Bowel DiseasesMargalida Calafat, Bharati Kochar, Ashwin N Ananthakrishnan
Pageof 42